Fiebelkorn K R, Crawford S A, Jorgensen J H
Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., MC 7750, San Antonio, TX 78229-3750, USA.
Antimicrob Agents Chemother. 2005 Feb;49(2):536-40. doi: 10.1128/AAC.49.2.536-540.2005.
Sulfonamide resistance in meningococci is associated with mutations in the chromosomal gene folP, which encodes dihydropteroate synthase. Several mutations associated with resistance have been previously described, including amino acid substitutions at codons 31 and 194, a glycine-serine insertion at codons 195 and 196, and, recently, an additional mutation at nucleotide 682 (C682A). In this study, sulfisoxazole MICs were determined for 424 geographically diverse clinical isolates of Neisseria meningitidis, including all major subtypes. A subset of 134 isolates with MICs ranging from 0.5 to >64 microg/ml were assayed for the C682A mutation by real-time PCR, and 25 isolates were selected for folP gene sequencing. All isolates for which the sulfisoxazole MIC was >/=8 possessed the C682A mutation by real-time PCR or folP sequencing, and 34 of 35 isolates with a MIC of </=2 lacked this mutation. Of 16 sequenced isolates for which the sulfisoxazole MIC was >/=4, 15 possessed previously described mutations, including 10 at codon 31, 1 at codon 194, and 4 with the 2-amino-acid insertion codons 195 and 196; all 16 possessed the C682A mutation. The C682A mutation predicted elevated sulfonamides MICs for a large number of geographically diverse clinical isolates of meningococci. Detection of this mutation by real-time PCR or other methods may allow more wide-scale detection of meningococcal isolates with for which the sulfonamide MICs are elevated without resorting to multiple assays or folP gene sequencing, providing a simple, high-throughput screening method for use in public health and epidemiologic settings.
脑膜炎球菌对磺胺类药物的耐药性与染色体基因folP中的突变有关,该基因编码二氢蝶酸合酶。先前已描述了几种与耐药性相关的突变,包括密码子31和194处的氨基酸替换、密码子195和196处的甘氨酸-丝氨酸插入,以及最近在核苷酸682处的另一种突变(C682A)。在本研究中,测定了424株来自不同地理区域的脑膜炎奈瑟菌临床分离株的磺胺异恶唑最低抑菌浓度(MIC),包括所有主要亚型。通过实时聚合酶链反应(PCR)对134株MIC范围为0.5至>64μg/ml的分离株进行C682A突变检测,并选择25株分离株进行folP基因测序。通过实时PCR或folP测序,所有磺胺异恶唑MIC≥8的分离株均具有C682A突变,35株MIC≤2的分离株中有34株缺乏该突变。在16株测序的磺胺异恶唑MIC≥4的分离株中,15株具有先前描述的突变,包括密码子31处的10个突变、密码子194处的1个突变以及密码子195和196处2个氨基酸插入的4个突变;所有16株均具有C682A突变。C682A突变预示着大量来自不同地理区域的脑膜炎球菌临床分离株的磺胺类药物MIC升高。通过实时PCR或其他方法检测该突变,可能无需进行多次检测或folP基因测序就能更广泛地检测到磺胺类药物MIC升高的脑膜炎球菌分离株,为公共卫生和流行病学环境提供一种简单、高通量的筛查方法。